Table 1.
Demographic Variables and Baseline Characteristics
| Characteristic | Entire Cohort | Weight Gain Category Subgroup | |||
|---|---|---|---|---|---|
| N=197 | Decelerated N=26 |
Average N=83 |
Accelerated N=88 |
P | |
| Age – years | 3.0 ± 0.6 | 3.3 ± 0.6 | 3.1 ± 0.6 | 3.0 ± 0.6 | .03 |
| Sex – no. (%) | .24 | ||||
| Male | 126 (64) | 20 (77) | 49 (59) | 57 (65) | |
| Female | 71 (36) | 6 (23) | 34 (41) | 31 (35) | |
| Race or Ethnic Group – no. (%) | .76 | ||||
| Non-Hispanic White | 114 (58) | 18 (69) | 51 (61) | 46 (52) | |
| Non-Hispanic Black | 22 (11) | 2 (8) | 7 (8) | 12 (14) | |
| Hispanic | 33 (17) | 3 (12) | 13 (16) | 18 (20) | |
| Other | 28 (14) | 3 (12) | 12 (14) | 12 (14) | |
| Birth Weight, Mean ± SD – kg | 3.4 ± 0.6 | 4.1 ± 0.4 | 3.5 ± 0.4 | 3.1 (0.5) | <.001 |
| Enrollment Weight, Mean ± SD – kg |
15.4 ± 2.4 | 14.8 ± 1.6 | 14.4 ± 1.8 | 16.5 ± 2.7 | <.001 |
| Positive Aeroallergen Skin Tests – no (%) |
122 (62) | 21 (81) | 54 (65) | 47 (53) | .03 |
| Eczema – no (%) | 105 (53) | 13 (50) | 48 (58) | 44 (50) | .56 |
| IgE, median (interquartile range) – IU/mL |
48.0 (13.7–115.0) | 97.4 (42.6–196.5) | 41.8 (13.1–97.1) | 40.2 (8.5–117.0) | .02 |
| Study Treatment Group | |||||
| Fluticasone – N (%) | 103 (52) | 17 (65) | 49 (59) | 37 (42) | 0.03 |
| Placebo – N (%) | 94 (48) | 9 (35) | 34 (41) | 51 (58) | |